YOLFTbeta
CervoMed Inc.

CervoMed Inc.

CRVO · NASDAQ · Healthcare / Biotechnology

1.69USD-0.14 (-7.65%)

Price History

Full chart

Market Stats

Previous Close1.83
Open1.75
Day Range1.64 – 1.79
52-Week Range2.13 – 10.00
Volume631.91K
Market Cap38.40M
P/E (TTM)0.00
Forward P/E0.00
EPS-3.27
Dividend Yield0.00%
Beta-4.31
50-Day Avg2.66
200-Day Avg4.22

About

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. John J. Alam M.D.
  • Employees15
  • Headquarters20 Park Plaza, Boston, MA, United States, 02116, USA
  • Websitehttps://www.cervomed.com

Leadership

  • Dr. John J. Alam M.D.Co-Founder, CEO, President & Director · b. 1962
  • Dr. Sylvie L. Gregoire Pharm.D.Co-Founder & Director · b. 1961
  • Mr. William Robert Elder J.D.CFO, General Counsel & Corporate Secretary · b. 1983
  • Ms. Kelly Blackburn M.H.A.Executive Vice President of Clinical Development · b. 1964
  • Dr. Marinus Verwijs Ph.D.Executive Vice President of Technical Operations · b. 1976
  • Dr. Mark A. De Rosch Ph.D.Executive VP of Regulatory, Government Affairs & Program Management · b. 1964
  • Dr. Claudia Ordonez M.D.Senior Vice President of Medical Science · b. 1966
  • Dr. Matthew Winton Ph.D.Chief Commercial & Business Officer · b. 1978

Financials

Income Statement

Currency: USD1998-12-311999-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue27.91M26.94M--308.76K40.19K-40.19K570.48K374.54K71.67K-----00007.14M9.74M4.01M
Growth (%)--3.49%----86.98%--+1319.48%-34.35%-80.87%----------+36.29%-58.86%
Cost of Revenue23.60M26.89M--134.15K24.68K47.20K210.39K2.31M235.80K675.76K566.26K8.27K25.34K67.98K110.37K97.92K103.17K93.42K1.34M8.44M18.80M-
Gross Profit4.31M48.06K--174.61K15.51K-47.20K-170.00K-1.74M138.74K-604.00K-566.00K-8.27K-25.34K-67.98K-110.00K-97.92K-103.17K-93.42K-1.34M-1.29M-9.06M-
Gross Margin15.45%0.18%--56.55%38.59%--423.00%-304.66%37.04%-842.79%----------18.11%-93.04%-
Operating Expense3.70M7.27M--3.06M2.24M2.90M7.47M14.69M11.93M7.31M6.77M6.40M14.85M11.28M11.92M11.45M15.87M24.58M14.64M6.52M9.17M-
Operating Income613.02K-7.22M-92.20K-41.90K-2.88M-2.22M-2.95M-7.64M-16.43M-11.79M-7.91M-7.34M-6.41M-14.87M-11.35M-12.03M-11.55M-15.97M-24.68M-15.97M-7.81M-18.23M-28.29M
Operating Margin2.20%-26.82%---934.06%-5528.88%--19002.71%-2879.88%-3148.38%-11039.95%----------109.35%-187.18%-706.22%
EBITDA813.02K-6.84M-92.20K-41.90K-2.45M-1.15M-3.23M-8.28M-22.48M-6.52M-1.55M-16.33M-6.40M-18.35M566.01K-18.70M-11.37M-15.76M-15.94M-3.48M-2.17M-16.29M-26.97M
EBITDA Margin2.91%-25.38%---792.20%-2866.46%--20600.16%-3941.45%-1740.26%-2168.36%----------30.40%-167.29%-673.06%
Net Income200.00K-8.06M-94.86K-48.10K-2.67M-2.09M-3.40M-8.41M-22.64M-6.87M-2.46M-14.35M-6.72M-18.04M-1.36M-18.37M-11.80M-14.19M-24.10M-15.59M-2.17M-16.29M-26.97M
Net Income Margin0.72%-29.92%---863.45%-5207.89%--20926.12%-3967.91%-1833.97%-3438.12%----------30.40%-167.29%-673.06%
R&D300.00K465.90K---------2.86M3.88M6.25M5.09M5.75M6.62M9.43M8.50M7.24M8.44M18.80M21.82M
R&D as % of Total Revenue1.07%1.73%------------------118.10%193.04%544.54%
Interest Expense500.00K-2.66K6.20K162.16K186.49K122.92K81.39K30.54K167.89K228.29K273.50K313.12K29.69K2.92M----5870--
Interest Expense % of Total Revenue1.79%---52.52%464.03%-202.52%5.35%44.83%318.55%---------0.00%--

Balance Sheet

Currency: USD1998-12-311999-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets18.50M22.18M--6.70M5.36M4.28M5.58M3.67M2.45M18.34M42.78M2.28M17.48M26.15M18.20M24.28M27.73M37.84M4.16M9.97M43.08M23.40M
Total Liabilities13.00M19.41M94.86K142.96K7.61M4.92M3.79M5.56M19.68M20.85M11.88M4.61M2.32M8.30M4.92M2.59M4.14M2.92M2.93M13.16M2.60M3.88M5.18M
Total Equity5.50M2.77M-94.86K-142.96K-905.93K438.99K493.60K20.22K-16.03M-18.39M6.46M38.17M-41.62K9.18M21.23M15.61M20.13M24.81M34.91M-9.00M7.38M39.20M18.22M
Cash-33.70K--196800--98.45K312.09K254.96K21.88M2.00M1.55M8.90M7.99M14.18M18.52M37.31M4.09M7.79M9.00M8.24M
Total Debt8.90M13.28M75.00K75.00K2.49M3.22M775.28K1.99M555.00K4.00M1.87M-1.24M2.43M550.00K-247.04K149.16K10.03M12.41M---
Net Debt8.90M13.25M75.00K75.00K2.49M3.21M775.28K1.99M456.55K3.69M1.61M-21.88M-753.58K877.15K-8.35M-7.99M-13.93M-18.37M-37.31M8.32M-7.79M-9.00M-8.24M

Cash Flow

Currency: USD1998-12-311999-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-7.10M-8.35M-75.00K---505.95K-1.06M-1.98M-12.02M-4.31M-1.18M-9.03M-5.19M-10.77M-12.33M-10.77M-9.86M-13.55M-14.50M-2.57M-7.45M-16.53M-23.45M
Investing Cash Flow-600.00K-944.06K-----213.12K-1.38M-985.89K---50.91K2.46M8.50M-447.82K---4.00K-12.24M--28.66M18.10M
Financing Cash Flow7.60M9.32M75.00K--506.55K1.27M3.37M13.11M4.52M1.13M30.71M2.39M1.83M20.12M9.87M16.04M17.89M33.30M5.00K11.15M46.40M4.59M
Capital Expenditure600.00K919.89K00001.12K13.64K125.00K0050.91K40.29K2.33K447.82K00001330
Free Cash Flow-7.70M-9.27M-75.00K---505.95K-1.06M-1.99M-12.15M-4.31M-1.18M-9.08M-5.23M-10.77M-12.78M-10.77M-9.86M-13.55M-14.50M-2.57M-7.45M-16.53M-23.45M
FCF to OCF108.45%111.02%100.00%--100.00%100.11%100.69%101.04%100.00%100.00%100.56%100.78%100.02%103.63%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateSep 30, 1998Dec 31, 1998Mar 31, 1999Mar 31, 2000Jun 30, 2000Sep 30, 2000Mar 31, 2007Jun 30, 2007Sep 30, 2007Mar 31, 2008Jun 30, 2008Sep 30, 2008Dec 31, 2008Mar 31, 2009Jun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Feb 25, 2015May 19, 2015Aug 13, 2015Nov 11, 2015Mar 28, 2016May 16, 2016Aug 10, 2016Nov 10, 2016Mar 24, 2017May 15, 2017Aug 21, 2017Nov 13, 2017Apr 3, 2018Aug 13, 2018Nov 14, 2018Mar 20, 2019May 9, 2019Aug 8, 2019Nov 11, 2019Mar 17, 2020May 11, 2020Aug 10, 2020Nov 12, 2020Mar 17, 2021May 7, 2021Aug 11, 2021Nov 10, 2021Mar 21, 2022May 12, 2022Aug 11, 2022Nov 14, 2022Mar 21, 2023May 15, 2023Aug 8, 2023Nov 13, 2023Mar 29, 2024May 14, 2024Aug 9, 2024Nov 12, 2024Mar 17, 2025Jun 13, 2025Aug 8, 2025Nov 7, 2025Mar 13, 2026May 19, 2026Aug 7, 2026Nov 6, 2026
EPS Estimate------------------------------------25.50-27.000.00--0.000.000.000.000.000.00-0.04-0.06-0.90-1.28-0.91-0.90-0.71-0.14-0.09-0.06-0.06-0.06-0.04-0.04-0.04-0.04-1.75-2.04-2.06-2.22-1.91-2.90-0.95-0.29-0.32-0.29-0.41-0.63-0.62-0.62-0.64-0.70-0.79-0.87-0.61
EPS Actual1000000.00-1000000.00-1000000.00-1000000.00-1000000.00-1000000.00-49881.33-405905.25-121086.111476.91-5853.54-5489.61-32644.68-8025.39-12287.12-11649.92-33583.54-74754.92-32977.37-14260.05-30032.28-62913.14-113439.46-31632.01-43051.84-43428.0724889.45-32786.439040.99-4140.75-1566.98-2616.40-3895.09-2078.43-3062.83-0.21-2398.87-7992.25-1879.80-700.39-417.23-7.950.00-1.77-0.540.200.38-56.25-146.25-124.50-60.75-47.25-45.0021.00-5.25-7.50-5.25-4.50-4.50-3.00-9.00-2.25-3.33-3.09-2.06-2.00-2.01-1.550.65-0.38-0.41-0.27-0.55-0.80-0.56-0.70-0.84-0.88-0.86-0.64-
Surprise-----------------------------------99.18%-8784.70%---------1050.00%-93650.00%-16150.00%-9626.56%-6575.82%-5150.00%-6238.03%15100.00%-5733.33%-12400.00%-9445.45%-8081.82%-9900.00%-6566.67%-22400.00%-5525.00%-90.29%-51.47%0.00%9.91%-5.24%46.42%168.42%-31.03%-28.13%6.90%-34.15%-26.98%10.16%-12.90%-31.25%-25.71%-8.46%26.44%-
Timing------------------------------------------------------------------Pre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hours---

Key Statistics & Ratios

Market Cap38.40M
Enterprise Value13.31M
Trailing P/E0.00
Forward P/E0.00
Price / Sales115.92
Price / Book1.67
EPS-3.27
Book Value1.70
Revenue (TTM)331.30K
Gross Profit (TTM)-21.00M
Profit Margin0.00%
Operating Margin-9406.96%
Return on Equity-107.62%
Return on Assets-60.80%
Shares Outstanding15.12M
Shares Float9.60M
Beta-4.31
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 7 analystsTarget 15.40
  • Strong Buy
    5
  • Buy
    1
  • Hold
    1

Ownership Breakdown

Institutions
22.29%
Insiders
26.43%
Retail / Other
51.28%

Top Institutional Holders

  • Morgan Stanley - Brokerage Accounts
    739.89K4.89%
  • Vanguard Capital Management, LLC
    316.20K2.09%
  • Geode Capital Management, LLC
    74.37K0.49%
  • Renaissance Technologies Corp
    63.90K0.42%
  • BlackRock Inc
    51.66K0.34%
  • Byrne Asset Management LLC
    51.25K0.34%
  • XTX Topco Ltd
    38.49K0.25%
  • Citizens Financial Group Inc
    37.48K0.25%
  • Vanguard Fiduciary Trust Co
    36.15K0.24%
  • Northern Trust Corp
    30.04K0.20%
  • Thompson Davis & Co Inc
    29.75K0.20%
  • Cetera Investment Advisers
    27.34K0.18%
  • Savvy Advisors Inc
    25.92K0.17%
  • State Street Corp
    20.53K0.14%
  • Jane Street Group LLC
    18.25K0.12%
  • Summit Financial LLC
    18.14K0.12%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    250.17K1.65%
  • Fidelity Extended Market Index
    73.06K0.48%
  • Abante Quant Value FI
    38.33K0.25%
  • iShares Micro-Cap ETF
    24.53K0.16%

Stock Splits

  • Aug 17, 20232:3
  • Apr 19, 20221:50
  • Dec 14, 20181:15
  • Aug 19, 20161:10
  • Mar 10, 20141:100